Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen
Curative treatment of stage I non-small-cell lung cancer with carbon ion beams using a hypofractionated regimen
复制标题
DOI：
10.1016/j.ijrobp.2006.10.006
复制
发表时间：
2007-03-01
影响因子：
7
通讯作者：
Fujisawa, Takehiko
中科院分区：
文献类型：
--
作者：
Miyamoto, Tadaaki;Baba, Masayuki;Fujisawa, Takehiko
目的：1994年至1999年首次进行了碳离子放射治疗I期非小细胞肺癌（NSCLC）的I/II期研究，并确定了最佳剂量。其次，进行了使用最佳剂量的II期研究。本研究的目的是澄清当地的控制和5年生存率。方法和材料：1999年4月至2000年12月，50例51原发病灶进行了治疗。使用固定剂量的72 GyE在9个分数超过3周，原发性肿瘤单独用碳离子束照射。患者的平均年龄为74.5岁。其中33例（66%）在医学上不可手术。局部控制和生存率采用Kaplan-Meier方法确定，数据采用log-rank test.Results进行统计学处理：所有患者均观察至少5年或直至死亡，中位随访时间为59.2个月（范围6.0-83.0个月）。局部控制率为94.7%。患者的5年病因特异性生存率为75.7%（IA：89.4; IB：55.1），总生存率为50.0%（IA：55.2; IB：42.9）。没有毒性反应，在肺大于3级detected.Conclusions：碳离子放疗，一种新的治疗方式，上级福利方面的生活质量和日常生活的活动，已被证明是一个有效的替代手术的I期非小细胞肺癌，并提供特别的好处，特别是对老年人和不能手术的患者。(c)2007年爱思唯尔公司
Purpose: A phase I/II study on carbon ion radiotherapy for Stage I non-small-cell lung cancer (NSCLC) was first conducted between 1994 and 1999 and determined the optimal dose. Second, a Phase II study using the optimal dose was performed. The purpose of the present study was to clarify the local control and 5-year survival rates.Methods and Materials: Between April 1999 and December 2000, 50 patients with 51 primary lesions were treated. Using a fixed dose of 72 GyE in nine fractions over 3 weeks, the primary tumors were irradiated with carbon ion beams alone. The average age of the patients was 74.5 years. Thirty-three (66%) of these were medically inoperable. Local control and survival were determined by using the Kaplan-Meier method and the data were statistically processed by using the log-rank test.Results: All patients were observed for a minimum of 5 years or until death with a median follow-up time of 59.2 months (range, 6.0-83.0 months). The local control rate for all patients was 94.7%. The patients' 5-year cause-specific survival rate was 75.7% (IA: 89.4; IB: 55.1), and overall survival 50.0% (IA: 55.2; IB: 42.9). No toxic reactions in the lung greater than Grade 3 were detected.Conclusions: Carbon ion radiotherapy, a new treatment modality with superior benefits in terms of quality of life and activity of daily living, has been proven as a valid alternative to surgery for Stage I NSCLC and to offer particular benefits, especially for elderly and inoperable patients. (c) 2007 Elsevier Inc.